Breezula (Clascoterone) for Hair Loss - Does It Work?
Last reviewed on 8 July 2026. We review our treatment guides every six months to keep them accurate.
Before we begin, one thing to be clear about from the outset: you cannot buy Breezula (clascoterone 5%) for hair loss in the UK, or anywhere else, at present. It is an investigational treatment that has completed late-stage trials but has not yet been submitted for approval or licensed for hair loss. The same molecule, at a lower strength, is already approved as an acne cream (Winlevi). Anyone offering the hair-loss version for sale today should be treated with caution. Always speak to a medical professional before considering any treatment.
For the latest official updates, see Cosmo Pharmaceuticals' news and press releases, the company developing the drug.
What is Breezula, and why has it drawn attention?
In December 2025, Cosmo Pharmaceuticals announced positive topline results from two large Phase III trials of clascoterone 5% topical solution (brand name Breezula) for male androgenetic alopecia. Twelve-month follow-up data followed in April 2026. In summary:
1,465 men were enrolled across two identically designed trials, SCALP 1 (NCT05910450) and SCALP 2 (NCT05914805), at 51 sites in the United States and Europe. This is the largest Phase III programme run for a topical male hair-loss treatment.
Both trials met their primary endpoint. Measured against the placebo vehicle, one study showed a 539% (5.39-fold) relative improvement in Target-Area Hair Count and the other a 168% (1.68-fold) relative improvement.
At twelve months, men who stayed on clascoterone had a statistically significant 239% (2.39-fold) greater improvement in hair count than men switched to the placebo vehicle after six months, suggesting benefit is maintained with continued use.
Safety and tolerability were reported as comparable to the placebo vehicle over the full year, with no significant systemic hormonal side effects and negligible systemic absorption.
Clascoterone is a topical androgen receptor inhibitor. It aims to block dihydrotestosterone (DHT) at the follicle rather than lowering hormone levels throughout the body.
Cosmo has said it plans to file for approval in the United States (FDA) and Europe (EMA), with a US submission targeted for early 2027.
These are company announcements and conference reports. Full results have not yet been published in a peer-reviewed journal, so the figures should be read as encouraging rather than settled.
So what is Breezula and why has it got attention?
Most men, and many women, seen for hair loss have androgenetic alopecia. The underlying process is well described. Dihydrotestosterone interacts with genetically sensitive hair follicles, gradually shortening the growth phase and producing finer, shorter hairs until visible thinning appears.
Current medical treatments tackle this in two main ways. Some aim to reduce the amount of dihydrotestosterone available. Finasteride is the clearest example. Others try to support hair growth despite ongoing hormonal pressure. Minoxidil sits firmly in this group.
Clascoterone approaches the problem from a different angle. Rather than reducing hormone levels, it aims to block the androgen receptor within the scalp itself, preventing dihydrotestosterone from delivering its signal at the follicle. Instead of reducing the body's production of DHT, as finasteride does, it attempts to stop DHT reaching the androgen receptor in the follicle by occupying that receptor first.
The idea of a local androgen blocker is not new in theory, but clascoterone is one of the first molecules to carry it through modern late-stage clinical development.
Breezula is the proposed brand name for clascoterone as a hair-loss treatment. The same active ingredient, at a lower 1% strength, is already approved as a topical acne cream under the brand name Winlevi, which has FDA approval in the United States and EMA approval in Europe. That tells you two things. First, regulators have accepted the general concept of a topical androgen receptor treatment for skin disease. Second, there is an existing safety record for the molecule that can inform the scalp programme, although the hair-loss formulation is a stronger 5% solution used on a different part of the body. The Journal of the American Academy of Dermatology sets out its mechanism, early studies and safety themes.
When applied to the scalp, the intent is direct receptor binding within the hair follicle environment. If androgen signalling can be slowed locally, miniaturisation may be slowed too. Slowing miniaturisation early can help preserve density, and preserving native hair can reduce the need for surgery or make a future hair transplant plan simpler.
How clascoterone works in practical terms
Hormone-driven hair loss has two broad steps. First, testosterone is converted into dihydrotestosterone. Second, dihydrotestosterone binds to receptors in the follicle and triggers miniaturisation.
Finasteride acts earlier in the chain by reducing the conversion step. That is why it works well for many men, and also why its side effects are discussed, because hormone levels can change throughout the body.
Clascoterone acts later in the chain. It is designed to sit on the androgen receptor within the skin and scalp, blocking dihydrotestosterone from binding and activating it. The intention is that hormone levels elsewhere in the body remain unchanged, and the trial data so far report negligible systemic absorption and no significant systemic hormonal side effects.
The challenge is delivery. The drug has to reach the follicle in sufficient concentration, stay there long enough to matter, and do so consistently over years rather than months. The Phase III programme suggests that, in controlled trial conditions and applied twice daily, this may be achievable, though everyday use outside a trial is a different test.
Does Breezula regrow hair or just slow loss?
This is where expectations need careful management, and only on a "what we know so far" basis. Most anti-androgen treatments do not behave like miracle regrowth solutions. Their primary role is to slow or stop further loss. Regrowth, when it occurs, usually reflects thickening of miniaturised hairs rather than the creation of entirely new follicles.
The clascoterone trials report improvements in Target-Area Hair Count compared with placebo, which points to some degree of regrowth. The trials measured change in vellus hair count (fine hairs up to around 30 micrometres in diameter) as their primary measure, alongside patients' own assessment of improvement. What is not yet available in full detail is the peer-reviewed breakdown: the absolute numbers, how much responses varied between individuals, and how well any gains hold up over the longer term.
A familiar pattern applies with medical treatments generally. Men with early thinning tend to respond better; those with long-standing bald areas rarely do. For that second group, a hair transplant remains the only reliable way to restore visible density.
What evidence supports Breezula so far?
Unlike finasteride or minoxidil, clascoterone does not yet have decades of published hair-loss data behind it. What it does have is a growing body of dermatology literature explaining its mechanism, two registered Phase III trials, and now twelve-month topline results reporting statistically significant outcomes.
A word of caution on the headline numbers is worth adding. A figure such as a 539% or 168% relative improvement describes how much better the drug did compared with placebo, not how many hairs a man actually gained. These endpoints are usually measured as extra hairs per square centimetre over a set period. If the placebo group gained very few hairs, a large percentage improvement on top of that can still be a small real-world change; if the placebo group gained more, the same percentage means a larger visible difference. That is why the absolute figures, once published in full, matter more than the percentages, and why the two trials producing quite different relative results (539% versus 168%) is itself worth understanding.
The Phase III trials are designed to answer the question regulators care about most. Does the treatment produce a real effect in a real population compared with placebo, and does it do so with an acceptable safety profile? On the company's account, both trials met their primary endpoint, benefit continued through twelve months of use, and long-term safety looked comparable to the placebo vehicle.
Topline data is not the end of the story. Cosmo has said it intends to publish the full dataset in a peer-reviewed journal and present it at dermatology conferences. Independent, published data will be needed to confirm the size of the benefit, how consistent the response is, and the long-term safety picture. Until then, any claim that Breezula will replace existing treatments is promising but premature.
Where Breezula stands in the UK
At present, clascoterone for hair loss is not a licensed treatment in the UK, and it is not yet available on prescription anywhere for that use. Cosmo has said it plans to seek approval in the United States and Europe, with a US filing targeted for early 2027. Approval, prescribing frameworks and real-world guidance all take further time after that.
This distinction matters. If you see clascoterone offered for hair loss through unregulated channels, the concern is not only legality but quality. Concentration, formulation and consistency are critical for a drug that relies on local delivery to the follicle.
Regulated care prioritises safety and follow-up, which protects you over the long term. If you are weighing up any hair-loss treatment, the sensible step is to speak to a medical professional rather than to source an unlicensed product.
How Breezula compares with finasteride
Finasteride remains one of the most effective medical options for many men with androgenetic alopecia. Its ability to reduce dihydrotestosterone has been demonstrated repeatedly, and its benefits in slowing hair loss are well established over many years of use.
Breezula does not challenge that evidence. It offers a different strategy. For men who cannot tolerate finasteride, or who prefer to avoid systemic hormone effects, a topical receptor blocker with negligible systemic absorption may in future become an attractive option. The decision about any medication should be made with a doctor who knows your history.
It is also possible that future treatment plans will combine approaches, using different mechanisms to protect follicles. Whether that adds meaningful benefit will depend on further data.
How Breezula compares with minoxidil
Minoxidil works through growth stimulation rather than hormone control. Many people see improvements in thickness or density with consistent use, particularly at the crown.
The limitation is that minoxidil does not address the underlying hormonal trigger. That is why gains can plateau or reverse if androgen pressure remains high. In that context, clascoterone would not be a replacement for minoxidil but a potential partner, targeting a different part of the problem.
Similar treatments: pyrilutamide, RU58841 and PP405
Clascoterone is not the only topical anti-androgen discussed online. Pyrilutamide (known as KX826 or Koshine 826) has been through formal clinical trials for hair loss and sits in a similar category as an androgen receptor blocker, although long-term data remains limited and its Phase III results were not as strong.
RU58841, by contrast, is a research compound with older experimental evidence and no modern regulatory approval for patient use. Despite frequent online discussion, it lacks the safety and quality framework required for responsible clinical care. From a UK medical perspective, that distinction is crucial.
A separate approach worth watching is PP405, an experimental topical drug aimed at reactivating dormant follicles. Where clascoterone blocks androgen signalling at the receptor, PP405 targets the stem cells within the follicle. Both remain investigational and both need larger, published data before any conclusions can be drawn.
Where hair transplants fit into this picture
Medical treatment and surgery are often framed as competing options. In reality they address different needs.
A hair transplant redistributes follicles to areas of visible loss. It does not stop ongoing miniaturisation elsewhere. Without medical support, transplanted hair can end up surrounded by thinning native hair, which can compromise the result.
Effective medical treatment helps protect both existing hair and the outcome of any surgery. If clascoterone becomes an approved option, it may offer another way to achieve that protection, particularly for men who cannot use finasteride. It is unlikely to be a cure on its own.
How Breezula is best understood today
Following the December 2025 and April 2026 announcements, a measured summary is as follows. Clascoterone represents a genuine scientific advance rather than marketing noise, and it targets the androgen pathway in a different way from existing treatments. The early results are encouraging, but full peer-reviewed data is still needed. It is not yet part of routine UK care, and it is not available to buy.
For anyone who already responds well to established treatments, there is no urgency to change. For those who cannot use them, clascoterone is worth watching closely. Any treatment decision should be made with a medical professional.
Frequently asked questions
Can I buy Breezula in the UK?
No. Clascoterone 5% for hair loss (Breezula) is investigational and not licensed anywhere for that use. It has completed Phase III trials, but Cosmo has said it plans to file for approval in the United States and Europe, with a US submission targeted for early 2027. Products sold online as "Breezula" for hair loss today are not the approved, quality-controlled medicine.
Is Breezula the same as Winlevi?
They share the same active ingredient, clascoterone, but they are different products. Winlevi is an approved 1% cream for acne. Breezula is the proposed name for a stronger 5% scalp solution being developed for hair loss. The acne approval does not mean the hair-loss version is approved.
Does clascoterone have finasteride-type side effects?
The trials so far report negligible systemic absorption and no significant systemic hormonal side effects, with tolerability comparable to the placebo vehicle over twelve months. That is a different profile from oral finasteride, which acts on hormone levels throughout the body. The full safety picture will become clearer once peer-reviewed data is published, and any medication should be discussed with a doctor.
Does Breezula work for women?
The SCALP 1 and SCALP 2 trials enrolled men with mild-to-moderate male-pattern hair loss. The results reported so far apply to men. Whether clascoterone helps women with hair loss has not been established in these trials and would need separate study.
What do the 539% and 168% figures actually mean?
They are relative improvements in hair count compared with placebo in the two trials, not the number of hairs gained. A large percentage can still be a modest real-world change if the placebo group gained few hairs, and a smaller percentage can be more meaningful if it did not. The absolute hair counts, once published in full, tell you more than the percentages, which is why independent peer-reviewed data is the figure to wait for.
When might Breezula be available in the UK?
There is no confirmed date. Cosmo has said it aims to submit for approval in the United States and Europe, with a US filing targeted for early 2027. Even in a favourable scenario, regulatory review and UK prescribing arrangements take time after a submission, so availability would be some way off. Following Cosmo's official updates is the most reliable way to track progress.
Get back to Great Hair
in 3 Easy Steps:
01
Arrange Free Consultation
Speak to one of our specialist consultants for expert advice on our range of different hair loss treatments
02
Book Your Procedure
Place a deposit to reserve a time slot at one of the My Hair UK clinics across the UK
03
Attend Your Surgery
Arrive on the day and our specialist surgical team will look after your every need
